medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2006; 5 (2)


Vanishing bile duct syndrome in a child with toxic epidermal necrolysis: An interplay of unbalanced immune regulatory mechanisms

Karnsakul W, Arkachaisri T, Atisook K, Wisuthsarewong W, Sattawatthamrong Y, Aanpreung P

Idioma: Ingles.
Referencias bibliográficas: 18
Paginas: 116-119
Archivo PDF: 108.74 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Srivastava M, Perez-Atayde A, Jonas MM. Drug-associated acuteonset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology 1998; 115: 743-6.

  2. Garcia M, Mhanna MJ, Chung-Park MJ, Davis PH, Srivastava MD. Efficacy of early immunosuppressive therapy in a child with carbamazepine-associated vanishing bile duct and Stevens-Johnson syndromes. Dig Dis Sci 2002; 47: 177-82.

  3. Sherlock S. The syndrome of disappearing intrahepatic bile ducts. Lancet 1987; 2: 493-6.

  4. Chamuleau RA, Diekman MJ, Bos PJ, Smitt JH, Bosma A, Schellekens PT. Reappearance of vanished bile ducts. Hepatogastroenterology 1992; 39: 523-4.

  5. Bruguera M, Llach J, Rodes J. Nonsyndromic paucity of intrahepatic bile ducts in infancy and idiopathic ductopenia in adulthood: the same syndrome? Hepatology 1992; 15: 830-4.

  6. O’Brien CB, Shields DS, Saul SH, Reddy KR. Drug-induced vanishing bile duct syndrome: response to ursodiol. Am J Gastroenterol 1996; 91: 1456-7.

  7. Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994; 20: 1437-41.

  8. Becker DS. Toxic epidermal necrolysis. Lancet 1998; 351: 1417-20.

  9. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-12.

  10. Revuz JE, Roujeau JC. Advances in toxic epidermal necrolysis. Semin Cutan Med Surg 1996; 15: 258-66.

  11. Stutts JT, Washington K, Bernard JA. Cholestatic jaundice with skin desquamation in a 12- year-old girl. J Pediatr 1999; 134: 649-53.

  12. Paquet P, Pierard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell’s syndrome). Int Arch Allergy Immunol 2005; 136: 205-16.

  13. Tangkanakul W, Smits HL, Jatanasen S, Ashford DA. Leptospirosis: an emerging health problem in Thailand. Southeast Asian J Trop Med Public Health 2005; 36: 281-8.

  14. Doudier B, Garcia S, Quennee V, Jarno P, Brouqui P. Prognostic factors associated with severe leptospirosis. Clin Microbiol Infect 2006; 12: 299-300.

  15. Nally JE, Chantranuwat C, Wu XY, Fishbein MC, Pereira MM, Da Silva JJ, Blanco DR, et al. Alveolar septal deposition of immunoglobulin and complement parallels pulmonary hemorrhage in a guinea pig model of severe pulmonary leptospirosis. Am J Pathol 2004; 164(3): 1115-27.

  16. Yao F, Behling CA, Saab S, Li S, Hart M, Lyche KD. Trimethoprimsulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol 1997; 92: 167-9.

  17. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP, Moreau A, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 15: 244-51.

  18. Smith LA, Ignacio JR, Winesett MP, Kaiser GC, Lacson AG, Gilbert-Barness E, Gonzalez-Peralta RP, et al. Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 2005; 41: 469-73.




2020     |     www.medigraphic.com